Hangzhou Biotest Biotech (688767.SH) releases a forecasted increase, with an estimated net profit of 170 million yuan in 2024, a year-on-year increase of 59.47%.

Hangzhou Biotest Biotech (688767.SH) announced that the company expects to achieve a net profit attributable to the owners of the parent company of approximately 170 million yuan in the year 2024. Compared with the same period last year (according to statutory disclosure data), it will increase by approximately 63.3942 million yuan, an increase of about 59.47% year-on-year.